Security Snapshot

UroGen Pharma Ltd. - Common Stock (URGN) Institutional Ownership

CUSIP: M96088105

13F Institutional Holders and Ownership History from Q2 2017 to Q3 2026

13F reference period

Q2 2026

Institutions Reporting

188

Shares (Excl. Options)

42.38MFull value: 42,380,184 · shares · 30 Jun 2026

Price

$36.80

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / Common Stock
Symbol
URGN on Nasdaq
All holders as of 30 Jun 2026
Q2 2026
Total 13F shares
42,380,184
Latest holder snapshot 5 signals
Total 13F value
$1,559,593,252
Portfolio coverage rank
0%
Share change
-4,057,165
Value change
-$44,922,069
Number of holders
188
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
48,549,968
SEC-reported price per share
$40.63
Insider filing price
$40.63
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • URGN - UroGen Pharma Ltd. - Common Stock is tracked under CUSIP M96088105.
  • 188 institutions reported positions in Q2 2026.
  • 8 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 172 to 188 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from
    $835.18MFull value: $835,175,547 · USD · 31 Mar 2026
    to
    $1.56BFull value: $1,559,593,252 · USD · 30 Jun 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 188 institutions filings for Q2 2026.

Open SEC evidence

Security key

M96088105

13F reference period

Q2 2026

13F holders

188

13D/G owners

8

CIK / CUSIP context first

Open Q2 2026 holders URGN full holder history UroGen Pharma Ltd. SEC filings UroGen Pharma Ltd. company facts UroGen Pharma Ltd. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
8
Security
URGN
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
TORONTO DOMINION BANK 6.7% +26% $129,196,001 +$25,809,631 3,269,957 +25% The Toronto-Dominion Bank 30 Jun 2026
BlackRock, Inc. 6.3% +22% $124,273,174 +$21,894,626 3,058,648 +21% BlackRock, Inc. 30 Sep 2026
MORGAN STANLEY 5.4% +180% $35,433,378 +$24,712,637 2,488,299 +231% Morgan Stanley 30 Jun 2025
MENORA MIVTACHIM HOLDINGS LTD. 5% $24,780,614 2,303,031 Menora Mivtachim Holdings Ltd 11 Mar 2025
Soleus Capital Master Fund, L.P. 4.7% -6% $31,114,400 -$1,993,600 2,185,000 -6% Soleus Capital Master Fund, L.P. 30 Jun 2025
Paradigm Biocapital Advisors LP 3.5% -61% $34,556,086 -$50,946,098 1,703,949 -60% Paradigm BioCapital Advisors LP 31 Mar 2026
Adage Capital Management, L.P. 2.8% -60% $13,740,520 -$17,765,685 1,277,000 -56% Adage Capital Management, L.P. 31 Mar 2025
Monograph Capital Holdings Advisors, LLC 1.8% $8,503,556 838,615 Monograph Capital Partners I, L.P. 05 Jun 2025
As of 30 Jun 2026, 188 institutional investors reported holding
42.38MFull value: 42,380,184 · shares · 30 Jun 2026
shares of UroGen Pharma Ltd. - Common Stock (URGN). This represents 87% of the company’s total
48.55MFull value: 48,549,968 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
74%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RTW INVESTMENTS, LP 9.4% 4,543,895 0% 1.4% $167,215,336
BlackRock, Inc. 6.6% 3,201,461 +13% 0% $117,813,765
MORGAN STANLEY 5.3% 2,576,363 +0.64% 0.01% $94,810,189
Kynam Capital Management, LP 5% 2,434,207 +8.3% 5% $89,578,818
Jefferies Financial Group Inc. 4.5% 2,199,652 0% 0.74% $80,947,194
SG Americas Securities, LLC 4.2% 2,052,906 +24% 0.04% $75,547,000
AMERICAN CENTURY COMPANIES INC 3.5% 1,685,719 +2.9% 0.03% $62,034,564
ACORN CAPITAL ADVISORS, LLC 3.4% 1,673,420 0% 17% $61,581,856
Point72 Asset Management, L.P. 3.1% 1,525,549 0.09% $56,140,203
FRONTIER CAPITAL MANAGEMENT CO LLC 3.1% 1,508,547 +15% 0.52% $55,514,521
Opaleye Management Inc. 3% 1,439,996 +0.7% 4.8% $52,991,853
SILVERARC CAPITAL MANAGEMENT, LLC 2.7% 1,301,979 -13% 5.3% $47,912,827
MENORA MIVTACHIM HOLDINGS LTD. 2.4% 1,152,531 0% 0.17% $42,413,141
D. E. Shaw & Co., Inc. 2.4% 1,145,819 +12% 0.03% $42,166,139
STATE STREET CORP 2.1% 1,003,071 +15% 0% $36,913,013
MPM BIOIMPACT LLC 1.9% 933,415 -1.1% 2.1% $34,349,672
Soleus Capital Management, L.P. 1.7% 829,810 +14% 1.1% $30,537,008
GOLDMAN SACHS GROUP INC 1.7% 819,834 +37% 0% $30,169,892
Migdal Insurance & Financial Holdings Ltd. 1.6% 770,909 0% 0.18% $28,369,451
ORBIMED ADVISORS LLC 1.4% 676,187 -23% 0.47% $24,883,682
GEODE CAPITAL MANAGEMENT, LLC 1.3% 610,364 +17% 0% $22,461,394
Woodline Partners LP 1% 500,726 0% 0.06% $18,426,717
Boxer Capital Management, LLC 1% 500,000 0% 1.4% $18,400,000
BANK OF AMERICA CORP /DE/ 0.98% 475,702 +275% 0% $17,505,834
VANGUARD PORTFOLIO MANAGEMENT LLC 0.94% 456,558 +11% 0% $16,801,334

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
38
Headline period
Q2 2026
Rows shown
1-25 of 38
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 424,507 $17,171,729 +$3,457,906 $40.63 29
2026 Q2 42,380,184 $1,559,593,252 -$44,922,069 $36.80 188
2026 Q1 46,442,204 $835,175,547 +$44,201,709 $17.98 172
2025 Q4 43,711,574 $1,023,591,933 +$14,662,063 $23.42 167
2025 Q3 43,904,765 $877,180,169 +$94,297,658 $19.95 159
2025 Q2 39,798,464 $545,161,051 +$3,475,596 $13.70 149
2025 Q1 41,643,932 $460,619,197 +$59,835,372 $11.06 139
2024 Q4 36,306,231 $386,611,717 -$9,614,830 $10.65 139
2024 Q3 35,097,143 $445,735,362 -$58,506,168 $12.70 127
2024 Q2 38,225,503 $641,423,803 +$207,327,873 $16.78 114
2024 Q1 27,162,024 $407,381,837 +$84,866,378 $15.00 111
2023 Q4 21,390,291 $320,854,510 +$51,912,609 $15.00 103
2023 Q3 17,724,118 $248,330,352 +$65,704,038 $14.01 100
2023 Q2 13,209,673 $136,728,106 +$7,180,182 $10.35 84
2023 Q1 12,428,895 $114,822,764 -$4,446,429 $9.24 64
2022 Q4 13,022,042 $115,449,037 -$2,381,858 $8.87 63
2022 Q3 13,319,758 $110,811,074 -$981,981 $8.32 56
2022 Q2 13,444,839 $109,243,080 -$6,040,297 $8.19 60
2022 Q1 14,223,995 $123,920,902 +$1,868,931 $8.71 82
2021 Q4 14,650,914 $139,360,752 +$2,176,410 $9.51 71
2021 Q3 14,085,432 $236,906,894 +$1,235,828 $16.82 88
2021 Q2 13,993,075 $213,691,867 -$5,527,357 $15.27 78
2021 Q1 14,299,652 $278,497,797 -$4,203,728 $19.48 88
2020 Q4 14,549,849 $261,548,580 -$10,506,654 $18.02 81
2020 Q3 15,009,007 $288,527,801 +$6,244,867 $19.29 78
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .